Please ensure Javascript is enabled for purposes of website accessibility

Open-Minded? Buy This Game-Changing Psychedelics Stock Now

By Alex Carchidi – Aug 26, 2021 at 7:39AM

Key Points

  • Psychedelic therapies face barriers to going mainstream, but progress is ongoing.
  • Developers can add value to psychedelic therapies in more ways than they can with a traditional drug product.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Excellent investing opportunities frequently seem outlandish.

When it comes to investing, open-mindedness is a virtue. Entertaining ideas outside the mainstream means you'll find opportunities that other people might reject or fail to recognize. In this vein, open-minded investors should definitely be watching the psychedelic therapy space very closely, because one of its leaders is on the cusp of something wonderful. 

Compass Pathways (CMPS 7.63%) will likely be the first healthcare company to bring a psychedelic therapy to market. While its business model relies on in-person clinical sessions that may be costly to administer, it's also one of the few psychedelics companies that has a plethora of opportunities to upsell patients on value-added services. And its much-vaunted training program for therapists could make it a key upstream supplier of skilled and credentialed labor for the rest of the psychedelics industry for years to come. Let's take a closer look at why these two tidbits make it a game-changing stock.

A psychologist sitting in an easy chair talks with a patient who is sitting on a couch with an engaged expression.

Image source: Getty Images.

An innovative approach makes for more opportunities to find value 

Compass' lead program for treatment-resistant depression, COMP360, isn't a typical biotech project. 

COMP360 is the combination of the psychedelic drug psilocybin and several sessions of psychological support from trained practitioners. The therapy is in phase 2b of clinical trials, and it's currently the world's largest clinical trial of psilocybin for any indication. It's also a bit complicated, so let's take a moment to understand how it works.

First, therapists prepare patients for their psychedelic experience with the help of the company's automated education platform. Then, they guide the patients through a talking therapy routine while they're under the drug's hallucinogenic effects, which last for around seven hours. All the while, patients rest comfortably in Compass' specially designed therapy rooms. Finally, the therapists help patients to build on their progress with more discussion sessions in the weeks after the psilocybin treatment. 

Compass is the only psychedelic company that's using its training program for therapists as a major center of value generation. Its curriculum includes supervised hands-on practice in cooperation with academic institutions, and improvements are constantly being made based on data from clinical trials. 

Having a training regimen is incredibly valuable, as it's part of the package which Compass will submit to regulators to prove that COMP360 is safe and effective. If the therapy is approved for sale, the training curriculum will become the first of its kind, and it's realistic to think competitors might want to license it to train their personnel. What's more, the company's curriculum could become a sought-after credential among mental health practitioners if and when psychedelic therapies become ever more common. 

The business's other major value-adding innovation is its control of the therapeutic environment. Compass' therapy rooms are designed to support therapeutic outcomes by providing a pleasant but neutral setting, thereby reducing the chance that a patient has a difficult experience. To my knowledge, no other psychedelic medicine company is taking this key factor into account as seriously as Compass. As a result, it has developed what may be a powerful force multiplier and important safety feature for its treatment. That'll support COMP360's efficacy in the clinic, and it'll also give the company the opportunity to command a significantly higher price once regulators have given the go-ahead. 

You might need to wait awhile to see returns

One important thing to know about Compass' stock is that it'll be at least a couple of years before its revenue starts to grow from administering its therapies, assuming they get regulatory approval. Another issue is that psilocybin is still heavily restricted and illegal at the federal level in the U.S., though a few jurisdictions have made some exceptions. So, there's a risk that COMP360 never makes it to the market if the legal landscape remains inflexible. 

Nonetheless, there are still a few upcoming catalysts which could make the stock worth owning in the short term. Before the end of the year, the company should report the full data from its phase 2b clinical trial. If the readout is favorable, expect the stock to jump in anticipation of the commencement of the final phase of the development process. Even if the data isn't what investors were hoping for, it might provide another good opportunity to buy the stock. 

Compass is also investigating in preclinical studies a smattering of conditions for which its lead candidate might also be effective, including Alzheimer's disease, chronic pain, epilepsy, and autism spectrum disorders. Given its favorable efficacy so far, it'd be surprising if there wasn't at least one other promising indication to move forward into clinical trials over the next couple of years.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends COMPASS Pathways plc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

COMPASS Pathways plc Stock Quote
COMPASS Pathways plc
CMPS
$10.30 (7.63%) $0.73

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
349%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.